Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTHER-2: Immunogenicity of Follitropin Delta in Repeated Ovarian Stimulation
NCT01956123Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- May 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, single-blind trial of follitropin delta in infertility (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Proportion of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies. Started Mar 2014; status: completed.
02
Drugs
follitropin delta
03
Conditions
infertility
Beyond the preview
Go deeper on NCT01956123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01956123.